Abstract 1928P
Background
Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas (incidence 0.15 and 0.51/106/year respectively, PMID: 33630918) with close/similar translocations whose natural history and optimal treatment are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010.
Methods
NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB). Since 2010, pathological review is mandatory for sarcoma patients and patients’ characteristics are collected in the NETSARC+ nationwide database. The characteristics of patients with SEF and LGFMS and their outcome are presented and compared.
Results
35/73 (47.9%) and 125/257(48,8%) of patients with SEF and LGFMS were female. More primary visceral, bone and trunk primary sites were observed in SEF (p<0.001). 30.1% of SEF vs 4.3% of LGFMS were metastatic at diagnosis (p<0.0001). Median size of the primary tumor was 51mm (range 10-90). For LGFMS vs 80mm (20-320) for SEF (p<0.001). Median age of LGFMS was 12 years younger than that of SEF (43 [range 4-98] vs 55 [range 10-91], p<0.001). Neoadjuvant treatment was more often given to SEF (16.4% vs 8.6%, p=0.05). More patients with LGFMS were operated first in reference centers (51% vs 26%, p<0.001).The R0 rate was 41% in LGFMS vs 16% in SEF (p<0.001). Median PFS of SEF and LGFMS were 32 and 136 months (p<0.0001) respectively. The median OS was not reached. 50-months OS was 92.6% vs 81% fr SEF (p=0.05). Median survival was 77 months after first relapse, similar for SEF and LGFMS. In multivariate analysis for PFS, SEF histotype, size of the tumor, met at diagnosis were independently correlated to survival. In multivariate analysis for OS, age, size of the tumor, met at diagnosis, but not SEF, independently correlated to survival.
Conclusions
Although sharing close molecular alterations, SEF and LGFMS have a very different natural history, clinical presentation and outcome with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, and similar for SEF and LGFMS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Leon Bérard for NETSARC+ Network.
Funding
NetSARC+ (INCA & DGOS) and RREPS (INCA & DGOS), RESOS (INCA & DGOS), LYRICAN+ (INCA-DGOS-INSERM 12563), Eurosarc (FP7-278742), InterSARC (INCA), LabEx DEvweCAN (ANR-10-LABX-0061), EURACAN (EC 739521), Association DAM’s, la Fondation ARC, Infosarcome, Ligue de L’Ain contre le Cancer, La Ligue contre le Cancer funded this study.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15